Alexium International Group Limited · ASX:AJX
Alexium International — H1 FY2022 Earnings Presentation
15 slides from Alexium International's earnings presentation, Feb 25, 2022
Slide 1: FY 2022 Half-Year Presentation
ALEXIUM FY 2022 HALF-YEAR PRESENTATION 25 February 2022 ASX: AJX
Slide 2: Disclaimer
Disclaimer To the maximum extent permitted by law, the information contained in this presentation is given without any liability whatsoever being accepted by Alexium International Group Limited (Alexium) or any of its related entities or their respective directors or officers, employees, advisors an
Slide 3: Company Overview
Alexium Company Overview Alexium is an advanced materials provider for thermal management and flame retardant applications Performance-driven products developed with environmentally-friendly materials and backed by granted/pending patents that secure the Company’s position in key markets Produ
Slide 4: Alexium Core Technologies
Alexium Core Technologies Alexicool® PCM-based cooling products for textile & foam applications Alexicool Biocool™ Biocool Proprietary biobased cooling products for textile & foam applications Eclipsys™ Eclipsys Perpetual cooling technology for textile- & foam-based products Alexiflam® Alexiflam Fla
Slide 5: Where We Are Today & Key Next Steps (Alexicool/Biocool)
& WHERE WE ARE KEY NEXT STEPS VALUE TO TODAY? IN 2H FY22 ALEXIUM • Alexicool®/Biocool brands are established • Continued revenue growth in textile as premium PCM-based products as applications in mattress & top-of-bed • New revenue streams shown with the recent award for applications • Improved prof
Slide 6: Where We Are Today & Key Next Steps (Eclipsys)
WHERE WE ARE KEY NEXT STEPS VALUE TO TODAY? IN 2H FY22 ALEXIUM • Eclipsys products are fully • Expanded market adoption of • New revenue streams commercialized for body armor Eclipsys to body armor manufacturers • Improved profit applications with first sales in 1H FY22 • Begin commercialisation of
Slide 7: Where We Are Today & Key Next Steps (Alexiflam/Alexiguard)
& WHERE WE ARE KEY NEXT STEPS VALUE TO TODAY? IN 2H FY22 ALEXIUM • Manufacturing and commercial partners • Support new customers • New revenue streams have support and validated Alexiflam® commercialisation efforts for has been validated through UL testing Alexiflam-based FR socks for foam • Improve
Slide 8: Success in FY2022
Success in FY2022 Major Achievements in 1H FY2022 Key Milestones for 2H FY2022 Strong year-over-year revenue growth Biocool Market Penetration Broader market penetration of BioCool™ FR NyCo work fully completed and products in bedding market transitioned to military to initiative their evaluations A
Slide 9: Half Year Financial Results
AY ALEXIUM Half Year Financial Results
Slide 10: Financial Snapshot
Financial Snapshot Strong revenue with BioCool™ product line Strong revenue growth of 46.3% vs 1H FY21 addition of BioCool™ products and new customers Net cash outflows from operating activities increased by $0.5m to ($0.9m) due to moderate increases in inventory purchases to support growth Op
Slide 11: Cash Flow Statement
Cash Flow Statement • Operating Activities outflows increased $0.5m with changes in: $1.8m – cash receipts ($2.0m) - product purchases & manufacturing ($0.3m) – all other costs All values in USD and thousands unless otherwise noted 11
Slide 12: Profit & Loss Statement
Profit & Loss Statement • Revenue growth from new customers and introduction of BioCool™ product line • Gross Profit up $1.0m with increased gross margin and revenue • Operating expenses increased $0.1m All values in USD and thousands unless otherwise noted 12
Slide 13: Balance Sheet
Balance Sheet • Working Capital • Overall working capital increased by $0.8M versus comparative period. Trade receivables & trade payables were lower and offset by an inventory increase to support increased revenue. • Non-Current Assets • Decrease of $0.4m due to minimal additions to fixed and intan
Slide 14: Non-GAAP Financial Measure Reconciliation
Non-GAAP Financial Measure Reconciliation Reconciliation of Operating EBITDA (non-GAAP financial measure) to statutory Net Profit/(Loss) HY22 HY21 (USD) (USD) The consolidated financial statements of the Group are general purpose Net Loss for the period (1,954) (1,794) financial statements which hav
Slide 15: @YALexium
@YALexium
Alexium International Group — H1 FY2022 Earnings Presentation on 6ix